Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems

Transfusion
Paul W Buehler, A I Alayash

Abstract

Several hemoglobin-based oxygen carriers (HBOCs) have been developed with a rationale focused on exploiting one or more physicochemical properties (e.g., oxygen affinity, molecular weight, viscosity, and colloid osmotic pressure) resulting from the chemical or recombinant modification of hemoglobin (Hb). Several chemically modified Hbs have reached late stages of clinical evaluation in the United States and Canada. These Hbs, in general, demonstrated mixed preclinical safety and efficacy, and reasonable safety in Phase I trials. However, as clinical development shifted into later stages, an undesirable safety and efficacy profile became clear in patient populations studied, and as a result some products were withdrawn from further clinical pursuit. Several questions still remain unanswered regarding the safety of Hb products for their proposed clinical indication(s). For example, 1) were preclinical studies predictive of clinical outcome? And, 2) were the most appropriate preclinical studies performed to predict clinical outcome? The primary objectives of this analysis are to explore prelinical safety issues associated with HBOCs and provide an overview of the in-vitro and in-vivo models employed. The methods for obtaining data...Continue Reading

References

Jan 1, 1978·Clinical Pharmacology and Therapeutics·J P SavitskyJ D Arnold
Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·J R HessR M Winslow
Jan 1, 1992·Biomaterials, Artificial Cells, and Immobilization Biotechnology : Official Journal of the International Society for Artificial Cells and Immobilization Biotechnology·J C HsiaR M Winslow
Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·M S MulliganP A Ward
Aug 1, 1990·The Journal of Surgical Research·M P Fink, S O Heard
Nov 15, 1990·Biochemical and Biophysical Research Communications·R G KilbournR F Lodato
Jan 1, 1988·Biomaterials, Artificial Cells, and Artificial Organs·L R SehgalG S Moss
Feb 1, 1987·Journal of Applied Physiology·E J BolandJ D Hellums
Jul 25, 1971·Biochimica Et Biophysica Acta·B S ShimY S Kang
Dec 21, 1973·Science·I B Chatterjee
Nov 1, 1969·Investigative Radiology·H N WagnerJ P Ryan
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·A G TsaiM Intaglietta
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·J R HessV Coppes
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·R I Roth, W Kaca
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·S S PanterR F Regan
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·M AzariJ Picken
Jan 1, 1994·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·S BushD Nelson
Jan 1, 1994·Archives of Surgery·A SauaiaD C Lezotte
Apr 30, 1993·Neuroscience Letters·R F Regan, S S Panter
May 1, 1993·Journal of Applied Physiology·R W GlennyM Brinkley
Oct 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·J BallaG M Vercellotti
Feb 1, 1993·Critical Care Medicine·D R Dantzker
Apr 1, 1993·Journal of Applied Physiology·J R HessW W Brinkley
Jan 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·C TiruppathiA B Malik
Jan 1, 1995·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·G P BiroP J Anderson
Jan 1, 1995·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·M C MardenC Poyart
Jan 1, 1996·Annals of Biomedical Engineering·J D HellumsN Ohshima
Jun 4, 1996·Biochemistry·R F EichJ S Olson
Apr 1, 1996·Journal of Neurotrauma·R F Regan, S S Panter
Nov 1, 1996·World Journal of Surgery·S A Gould, G S Moss
Dec 1, 1996·The Journal of Laboratory and Clinical Medicine·S M MuldoonV W Macdonald
Jan 1, 1997·Free Radical Biology & Medicine·J Everse, N Hsia
Mar 1, 1997·The Journal of Laboratory and Clinical Medicine·J L HartS M Muldoon
Jan 1, 1997·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·A KumarA Gulati
Jan 1, 1997·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·F D'Agnillo, T M Chang

❮ Previous
Next ❯

Citations

May 19, 2007·Antioxidants & Redox Signaling·Dominik J SchaerPaul W Buehler
Aug 8, 2009·Antioxidants & Redox Signaling·Paul W Buehler, Felice D'Agnillo
Sep 4, 2012·Antioxidants & Redox Signaling·Pedro Cabrales
Apr 25, 2006·Critical Care Medicine·Amy G Tsai, Pedro Cabrales
Jul 2, 2005·Transfusion·Toby SilvermanKimberly Lindsey
Jul 13, 2006·Annual Review of Biomedical Engineering·Marcos IntagliettaAmy G Tsai
Mar 19, 2014·Trends in Biotechnology·Abdu I Alayash
May 5, 2007·Expert Opinion on Biological Therapy·Abdu I AlayashPaul W Buehler
Jun 27, 2013·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·Erik C BrockmanPatrick M Kochanek
May 3, 2008·Biochimica Et Biophysica Acta·Anna Maria PirasElena Della Valle
Jan 22, 2008·Biochimica Et Biophysica Acta·Paul W Buehler, Abdu I Alayash
Dec 23, 2006·Biochimica Et Biophysica Acta·Aleksandra KowalczykEligiusz Serafin
Feb 6, 2009·Biotechnology Progress·David Raphael Harris, Andre Francis Palmer
Jan 6, 2009·Vox Sanguinis·H BuchwaldJ Gorlin
Nov 10, 2007·Journal of Veterinary Pharmacology and Therapeutics·P PawsonF J Dowell
Jul 4, 2006·Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis·C C M LelkensF Noorman
Dec 6, 2005·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·C P Stowell
Nov 9, 2006·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·Kenneth C Lowe
Aug 27, 2014·Free Radical Biology & Medicine·Salvador PérezJuan Sastre
Mar 16, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Anirban Sen Gupta
Jan 19, 2017·PloS One·Vivek P JaniPedro Cabrales
Apr 15, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Kazuaki TaguchiMasaki Otagiri
Feb 1, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Hiromi SakaiMarcos Intaglietta

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.